

Peeter Karihtala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8851766/publications.pdf>

Version: 2024-02-01

91
papers

2,271
citations

257450

24
h-index

254184

43
g-index

91
all docs

91
docs citations

91
times ranked

4220
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 443-450.	2.5	3
2	How breast cancer recurrences are found – a real-world, prospective cohort study. <i>Acta Oncologica</i> , 2022, 61, 417-424.	1.8	0
3	NRF3 Decreases during Melanoma Carcinogenesis and Is an Independent Prognostic Marker in Melanoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-10.	4.0	2
4	Association of Metformin, Other Antidiabetic Medications, and Statins With Incidence of Colon Cancer in Patients With Type 2 Diabetes. <i>Clinical Colorectal Cancer</i> , 2021, 20, e113-e119.	2.3	5
5	Real-world, single-centre prospective data of age at breast cancer onset: focus on survival and reproductive history. <i>BMJ Open</i> , 2021, 11, e041706.	1.9	2
6	Metformin Associates With Aggressive Features of Endometrial Cancer in Women With Type 2 Diabetes. <i>Anticancer Research</i> , 2021, 41, 821-828.	1.1	4
7	Early-Life Risk Factors for Breast Cancer – Prospective Follow-up in the Northern Finland Birth Cohort 1966. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 616-622.	2.5	0
8	Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 10445.	3.3	5
9	No Association Between Statin Use and the Prognosis of Endometrial Cancer in Women With Type 2 Diabetes. <i>Frontiers in Pharmacology</i> , 2021, 12, 621180.	3.5	1
10	Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?. <i>Frontiers in Oncology</i> , 2021, 11, 683570.	2.8	19
11	Bacterial Extracellular Vesicles in Gastrointestinal Tract Cancer: An Unexplored Territory. <i>Cancers</i> , 2021, 13, 5450.	3.7	14
12	Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. <i>Investigational New Drugs</i> , 2020, 38, 181-193.	2.6	70
13	Prognostic factors in metastatic breast cancer: a prospective single-centre cohort study in a Finnish University Hospital. <i>BMJ Open</i> , 2020, 10, e038798.	1.9	12
14	High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study. <i>Frontiers in Oncology</i> , 2020, 10, 1470.	2.8	10
15	Early progression of breast cancer during neoadjuvant chemotherapy may predict poorer prognoses. <i>Acta Oncologica</i> , 2020, 59, 1036-1042.	1.8	2
16	Survival after breast cancer in women with type 2 diabetes using antidiabetic medication and statins: a retrospective cohort study. <i>Acta Oncologica</i> , 2020, 59, 1110-1117.	1.8	12
17	Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma. <i>Annals of Hematology</i> , 2020, 99, 1823-1831.	1.8	14
18	Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment. <i>European Journal of Haematology</i> , 2020, 105, 156-163.	2.2	2

#	ARTICLE	IF	CITATIONS
19	Metformin and ovarian cancer: the evidence. <i>Annals of Translational Medicine</i> , 2020, 8, 1711-1711.	1.7	22
20	Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?. <i>Annals of Translational Medicine</i> , 2020, 8, 1706-1706.	1.7	17
21	Wise Management of Ovarian Cancer: On the Cutting Edge. <i>Journal of Personalized Medicine</i> , 2020, 10, 41.	2.5	51
22	Incidence of solid cancer in patients with follicular lymphoma. <i>Acta Oncologica</i> , 2019, 58, 1564-1569.	1.8	5
23	Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review. <i>Diagnostics</i> , 2019, 9, 87.	2.6	94
24	Elevated preoperative serum levels of collagen I carboxyterminal telopeptide predict better outcome in early-stage luminal-B-like (HER2-negative) and triple-negative subtypes of breast cancer. <i>Tumor Biology</i> , 2019, 41, 101042831984708.	1.8	5
25	Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer. <i>Scientific Reports</i> , 2019, 9, 10961.	3.3	63
26	High baseline Tie1 level predicts poor survival in metastatic breast cancer. <i>BMC Cancer</i> , 2019, 19, 732.	2.6	12
27	Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era. <i>British Journal of Haematology</i> , 2019, 187, 364-371.	2.5	11
28	Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma. <i>Anticancer Research</i> , 2019, 39, 4925-4931.	1.1	0
29	NRF1 and NRF2 mRNA and Protein Expression Decrease Early during Melanoma Carcinogenesis: An Insight into Survival and MicroRNAs. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-15.	4.0	16
30	Cytoplasmic Mineralocorticoid Receptor Expression Predicts Dismal Local Relapse-free Survival in Non-triple-negative Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 5879-5890.	1.1	6
31	Cytoplasmic Keap1 Expression Is Associated With Poor Prognosis in Endometrial Cancer. <i>Anticancer Research</i> , 2019, 39, 585-590.	1.1	8
32	Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent Long-Term Survival in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, e522-e533.	2.4	27
33	Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 741-748.	2.5	9
34	Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP. <i>Journal of Clinical Pathology</i> , 2019, 72, 316-321.	2.0	12
35	Expression Levels of microRNAs miR-93 and miR-200a in Pancreatic Adenocarcinoma with Special Reference to Differentiation and Relapse-Free Survival. <i>Oncology</i> , 2019, 96, 164-170.	1.9	15
36	Metformin diminishes the unfavourable impact of Nrf2 in breast cancer patients with type 2 diabetes. <i>Tumor Biology</i> , 2019, 41, 101042831881541.	1.8	10

#	ARTICLE	IF	CITATIONS
37	Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A. <i>Oncology</i> , 2019, 96, 147-155.	1.9	7
38	Rare missense mutations in <i>RECQL</i> and <i>POLG</i> associate with inherited predisposition to breast cancer. <i>International Journal of Cancer</i> , 2018, 142, 2286-2292.	5.1	15
39	High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 223.	2.6	25
40	Low Rap1-interacting factor 1 and sirtuin 6 expression predict poor outcome in radiotherapy-treated Hodgkin lymphoma patients. <i>Leukemia and Lymphoma</i> , 2018, 59, 679-689.	1.3	3
41	Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP. <i>Scientific Reports</i> , 2018, 8, 14814.	3.3	21
42	Toll-like receptors 2, 4 and 9 and hypoxia markers <i>HIF-1</i> alpha and <i>CAIX</i> in pancreatic intraepithelial neoplasia. <i>Apmis</i> , 2018, 126, 852-863.	2.0	14
43	Proteins of the retinoblastoma pathway, FEN1 and MGMT are novel potential prognostic biomarkers in pancreatic adenocarcinoma. <i>Pathology Research and Practice</i> , 2018, 214, 840-847.	2.3	8
44	Strong Prolyl Hydroxylase Domain 1 Expression Predicts Poor Outcome in Radiotherapy-treated Patients with Classical Hodgkin's Lymphoma. <i>Anticancer Research</i> , 2018, 38, 329-336.	1.1	5
45	KDM4D Predicts Recurrence in Exocrine Pancreatic Cells of Resection Margins from Patients with Pancreatic Adenocarcinoma. <i>Anticancer Research</i> , 2018, 38, 2295-2302.	1.1	8
46	Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study. <i>BMC Cancer</i> , 2017, 17, 72.	2.6	27
47	Exploring effects of remote ischemic preconditioning in a pig model of hypothermic circulatory arrest. <i>Scandinavian Cardiovascular Journal</i> , 2017, 51, 233-241.	1.2	9
48	Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma. <i>Carcinogenesis</i> , 2017, 38, 812-820.	2.8	20
49	Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer. <i>ESMO Open</i> , 2017, 2, e000202.	4.5	10
50	Exploring Spinal Cord Protection by Remote Ischemic Preconditioning: An Experimental Study. <i>Annals of Thoracic Surgery</i> , 2017, 103, 804-811.	1.3	12
51	Prognostic and predictive role of spatially positioned tumour infiltrating lymphocytes in metastatic HER2 positive breast cancer treated with trastuzumab. <i>Scientific Reports</i> , 2017, 7, 18027.	3.3	21
52	Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-11.	4.0	128
53	The Role of Redox-Regulating Enzymes in Inoperable Breast Cancers Treated with Neoadjuvant Chemotherapy. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-9.	4.0	4
54	Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-8.	4.0	17

#	ARTICLE	IF	CITATIONS
55	An immunohistochemical study of NFE2L2, KEAP1 and 8-hydroxy-2'-deoxyguanosine and the EMT markers SNAI2, ZEB1 and TWIST1 in metastatic melanoma. <i>Histology and Histopathology</i> , 2017, 32, 129-136.	0.7	9
56	Remote Ischemic Preconditioning Reduces Cerebral Oxidative Stress Following Hypothermic Circulatory Arrest in a Porcine Model. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2016, 28, 92-102.	0.6	7
57	Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 623-630.	2.8	3
58	Remote Ischemic Preconditioning Attenuates Oxidative Stress during Cardiopulmonary Bypass. <i>Heart Surgery Forum</i> , 2016, 19, 192.	0.5	8
59	Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma. <i>Anticancer Research</i> , 2016, 36, 4677-4684.	1.1	14
60	Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer. <i>Anticancer Research</i> , 2016, 36, 6431-6438.	1.1	21
61	Loss of Peroxiredoxin Expression Is Associated with an Aggressive Phenotype in Pancreatic Adenocarcinoma. <i>Anticancer Research</i> , 2016, 36, 427-33.	1.1	5
62	Nrf2/Keap1 Pathway and Expression of Oxidative Stress Lesions 8-hydroxy-2'-deoxyguanosine and Nitrotyrosine in Melanoma. <i>Anticancer Research</i> , 2016, 36, 1497-506.	1.1	29
63	Cancer Stem Cell Properties as Factors Predictive of Chemoresistance in Neoadjuvantly-treated Patients with Ovarian Cancer. <i>Anticancer Research</i> , 2016, 36, 3425-31.	1.1	22
64	Male Malignant Phyllodes Breast Tumor After Prophylactic Breast Radiotherapy and Bicalutamide Treatment: A Case Report. <i>Anticancer Research</i> , 2016, 36, 3433-6.	1.1	5
65	Keap1 expression has independent prognostic value in pancreatic adenocarcinomas. <i>Diagnostic Pathology</i> , 2015, 10, 28.	2.0	16
66	Dysregulation of redox state-regulating enzymes in melanocytic skin tumours and the surrounding microenvironment. <i>Histopathology</i> , 2015, 67, 348-357.	2.9	13
67	High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index. <i>Journal of Clinical Pathology</i> , 2015, 68, 552-556.	2.0	8
68	Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer. <i>BMC Cancer</i> , 2015, 15, 493.	2.6	20
69	Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas. <i>Histopathology</i> , 2014, 65, 319-327.	2.9	34
70	Metformin decreases serum 8-hydroxy-2'-deoxyguanosine levels in polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2013, 99, 593-598.	1.0	20
71	Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma. <i>Histopathology</i> , 2013, 62, 326-333.	2.9	52
72	Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 81-90.	2.5	116

#	ARTICLE	IF	CITATIONS
73	Expression and prognostic evaluation of oxidative stress markers in an immunohistochemical study of B-cell derived lymphomas. <i>Leukemia and Lymphoma</i> , 2012, 53, 624-631.	1.3	22
74	Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma. <i>Experimental Hematology and Oncology</i> , 2012, 1, 2.	5.0	27
75	Down-regulation of 8-hydroxydeoxyguanosine and peroxiredoxin II in the pathogenesis of endometriosis-associated ovarian cancer. <i>Anticancer Research</i> , 2012, 32, 3037-44.	1.1	11
76	Divergent behaviour of oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and 4-hydroxy-2-nonenal (HNE) in breast carcinogenesis. <i>Histopathology</i> , 2011, 58, 854-862.	2.9	58
77	Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. <i>BMC Cancer</i> , 2011, 11, 262.	2.6	67
78	Hypoxia and Oxidative Stress in the Pathogenesis of Gynecological Cancers and in Therapeutical Options. <i>Current Cancer Therapy Reviews</i> , 2011, 7, 37-55.	0.3	10
79	8-hydroxydeoxyguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2011, 4, 267-75.	0.5	40
80	Elevated serum 8-OHdG is associated with poor prognosis in epithelial ovarian cancer. <i>Anticancer Research</i> , 2011, 31, 1411-5.	1.1	24
81	Long-term observational follow-up study of breast cancer diagnosed in women ≥ 40 years old. <i>Breast</i> , 2010, 19, 456-461.	2.2	19
82	Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis. <i>European Journal of Cancer</i> , 2010, 46, 1661-1667.	2.8	46
83	Distinctively low levels of serum 8-hydroxydeoxyguanosine in women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2010, 94, 2670-2673.	1.0	19
84	Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial. <i>Anticancer Research</i> , 2010, 30, 1001-6.	1.1	10
85	DNA Adduct 8-Hydroxydeoxyguanosine, a Novel Putative Marker of Prognostic Significance in Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1047-1051.	2.5	59
86	Hyaluronan in Breast Cancer: Correlations With Nitric Oxide Synthases and Tyrosine Nitrosylation. <i>Journal of Histochemistry and Cytochemistry</i> , 2007, 55, 1191-1198.	2.5	33
87	Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies.. <i>Apmis</i> , 2007, 115, 81-103.	2.0	283
88	Increasing oxidative damage and loss of mismatch repair enzymes during breast carcinogenesis. <i>European Journal of Cancer</i> , 2006, 42, 2653-2659.	2.8	26
89	Thioredoxin is associated with proliferation, p53 expression and negative estrogen and progesterone receptor status in breast carcinoma. <i>Apmis</i> , 2004, 112, 123-132.	2.0	33
90	Antioxidative response for nitric oxide production in breast carcinoma. <i>Oncology Reports</i> , 2004, 12, 755-9.	2.6	12

#	ARTICLE	IF	CITATIONS
91	Peroxiredoxins in breast carcinoma. <i>Clinical Cancer Research</i> , 2003, 9, 3418-24.	7.0	156